Becton Dickinson & CO Form 4 insider transactions

Becton Dickinson & Co. EVP Michael Feld sold 57 shares of common stock for $186.01 per share under a pre-arranged 10b5-1 plan.

Becton Dickinson EVP Michael Feld sold 58 shares of common stock for $181.03 per share on September 26, 2025, under a pre-arranged 10b5-1 plan.

Becton Dickinson & Co. Director Claire Fraser filed a Form 4 indicating a future sale of 917 shares of common stock at $187.50 per share, executed under a 10b5-1 plan.

Becton Dickinson's EVP & CFO, Christopher DelOrefice, reported the withholding of 278 common shares for tax obligations related to restricted stock unit vesting.

Becton Dickinson EVP & President Interventional, Richard Byrd, reported the withholding of 216 common shares for tax obligations related to restricted stock unit vesting.

Becton Dickinson & Co. EVP Michael Feld sold 57 shares of common stock for $197.99 per share, executed under a pre-arranged 10b5-1 trading plan.

Becton, Dickinson and Company's EVP & President, Life Sciences, Michael Feld, reported a disposition of 773 common shares for tax withholding purposes.

Becton Dickinson & Co. Director Gregory Hayes acquired 5,250 shares of common stock at $191.57 per share, increasing his direct beneficial ownership to 6,046 shares.

Becton Dickinson Director Claire Fraser reported the sale of 863 common shares at $192.30 per share, reducing her direct beneficial ownership.

Becton Dickinson director Christopher Jones acquired additional rights to common stock through the company's deferred compensation plan, signaling continued confidence.

Becton Dickinson Director Carrie L. Byington reported the acquisition of 34 rights to common stock under a deferred compensation plan, effective August 7, 2025.

Becton Dickinson's EVP & President, Medical, Michael David Garrison, reported the exercise of stock appreciation rights and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Waters Corporation and Becton, Dickinson and Company announced a definitive agreement for Waters to acquire BD's Biosciences & Diagnostic Solutions business via a Reverse Morris Trust, creating a life science and diagnostic leader with pro-forma revenue of $6.5 billion and adjusted EBITDA of $2 billion for 2025.

Waters Corporation and Becton, Dickinson and Company's biosciences and diagnostic solutions business, Augusta SpinCo Corporation, are combining to form a leading life science company, aiming to double the addressable market to $40 billion and enhance financial performance.

Becton, Dickinson and Company has filed a Rule 425 communication with the SEC regarding the proposed business combination of its biosciences and diagnostic solutions business, Augusta SpinCo Corporation, with Waters Corporation, outlining forward-looking statements and associated risks.

Waters Corporation and Becton, Dickinson and Company (BD) announced their intent to combine BD's Biosciences and Diagnostic Solutions business with Waters, aiming to create a leading life science and diagnostics company focused on regulated, high-volume testing.

Becton, Dickinson and Company (BD) has entered into definitive agreements to combine its Biosciences and Diagnostic Solutions business with Waters Corporation through a Reverse Morris Trust transaction, which will result in BD receiving approximately $4 billion in cash and BD shareholders owning 39.2% of Waters' outstanding common stock post-transaction.

Waters Corporation and Becton, Dickinson and Company announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction, forming an innovative life science and diagnostics leader.

Waters Corporation and Becton, Dickinson & Company's Biosciences & Diagnostic Solutions business will combine in a $17.5 billion Reverse Morris Trust transaction, aiming to create a leading life science and diagnostics company with significant market expansion and synergy potential.

Bilal Muhsin, EVP & President Connected Care at Becton, Dickinson and Company, was granted 12,221 shares of common stock as restricted stock units.

Becton Dickinson's EVP and Chief ISC Officer, David Shan, sold 1,166 shares of common stock for $171.19 per share, as part of a pre-established Rule 10b5-1 trading plan.

Director Christopher Ian Montague Jones acquired 145 rights to common stock under Becton Dickinson's deferred compensation plan on May 6, 2025.

Director Carrie L Byington acquired 29 rights to common stock under Becton Dickinson's Deferred Compensation Plan on May 6, 2025.

Michael David Garrison, EVP & President, Medical at Becton Dickinson, sold 479 shares of common stock at a price of $197.28 per share on April 9, 2025, under a pre-arranged 10b5-1 trading plan.

Shana Carol Neal, EVP and Chief People Officer at Becton Dickinson, reports disposition of shares for tax withholding upon vesting of restricted stock units.

Director Gregory Hayes reports acquisition of 796 restricted stock units in Becton Dickinson & Co. on March 26, 2025.

Richard Byrd, EVP & President Interventional at Becton Dickinson & Co, reports the sale of 459 shares of common stock at $230 per share on March 18, 2025.

Richard Byrd, EVP & President Interventional at Becton Dickinson & Co, sold 1,940 shares of common stock at a price of $224.91 on March 12, 2025, under a pre-arranged 10b5-1 trading plan.

Michael David Garrison, an EVP at Becton Dickinson, reports a transaction involving common stock related to the vesting of restricted stock units.

Director Bertram L. Scott of Becton Dickinson sold 700 shares of common stock at a price of $227.99 on February 12, 2025.